DE60330266D1 - Verfahren zur beurteilung der wirksamkeit von chemotherapeutika - Google Patents

Verfahren zur beurteilung der wirksamkeit von chemotherapeutika

Info

Publication number
DE60330266D1
DE60330266D1 DE60330266T DE60330266T DE60330266D1 DE 60330266 D1 DE60330266 D1 DE 60330266D1 DE 60330266 T DE60330266 T DE 60330266T DE 60330266 T DE60330266 T DE 60330266T DE 60330266 D1 DE60330266 D1 DE 60330266D1
Authority
DE
Germany
Prior art keywords
methods
assessing
chemotherapeutic
effectiveness
chemotherapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330266T
Other languages
English (en)
Inventor
Paul L Kornblith
Sean Mcdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Predictive Oncology Inc
Original Assignee
Precision Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Therapeutics Inc filed Critical Precision Therapeutics Inc
Application granted granted Critical
Publication of DE60330266D1 publication Critical patent/DE60330266D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
DE60330266T 2002-10-10 2003-10-10 Verfahren zur beurteilung der wirksamkeit von chemotherapeutika Expired - Lifetime DE60330266D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41743902P 2002-10-10 2002-10-10
US10/336,659 US20040072722A1 (en) 2002-10-10 2003-01-02 Methods for assessing efficacy of chemotherapeutic agents
PCT/US2003/032285 WO2004035833A1 (en) 2002-10-10 2003-10-10 Methods for assessing efficacy of chemotherapeutic agents

Publications (1)

Publication Number Publication Date
DE60330266D1 true DE60330266D1 (de) 2010-01-07

Family

ID=32072939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330266T Expired - Lifetime DE60330266D1 (de) 2002-10-10 2003-10-10 Verfahren zur beurteilung der wirksamkeit von chemotherapeutika

Country Status (6)

Country Link
US (4) US20040072722A1 (de)
EP (1) EP1556515B1 (de)
AT (1) ATE449869T1 (de)
AU (1) AU2003285866A1 (de)
DE (1) DE60330266D1 (de)
WO (1) WO2004035833A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072722A1 (en) 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
US20040023375A1 (en) 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US5728541A (en) * 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20070087401A1 (en) * 2003-10-17 2007-04-19 Andy Neilson Analysis of metabolic activity in cells using extracellular flux rate measurements
US8658349B2 (en) 2006-07-13 2014-02-25 Seahorse Bioscience Cell analysis apparatus and method
US7042565B2 (en) * 2004-02-13 2006-05-09 Kaiwood Technology Co., Ltd. Fluorescent microarray analyzer
JP2009506777A (ja) * 2005-09-01 2009-02-19 プレシジョン セラピューティクス，インコーポレイテッド 抵抗性の表現型特徴を示す腫瘍細胞を用いた化学療法感受性アッセイ
CA2631236C (en) * 2005-12-01 2019-10-29 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2136630A4 (de) * 2007-03-23 2010-06-02 Precision Therapeutics Inc Verfahren zur auswertung des angiogenen potentials in kultur
EP2207892A4 (de) * 2007-10-15 2010-12-08 Precision Therapeutics Inc Verfahren zur selektion aktiver agentien für die krebsbehandlung
US20100311084A1 (en) * 2008-05-14 2010-12-09 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
US8202702B2 (en) * 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US20110238322A1 (en) * 2008-11-03 2011-09-29 Precision Therapeutics, Inc. Methods of simulating chemotherapy for a patient
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
US20110097748A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Use of cell lines to determine levels of efficacy of pharmaceutical formulations
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
WO2013063530A2 (en) 2011-10-28 2013-05-02 Presage Biosciences, Inc. Methods for drug delivery
US9494577B2 (en) 2012-11-13 2016-11-15 Seahorse Biosciences Apparatus and methods for three-dimensional tissue measurements based on controlled media flow
CN104956226B (zh) 2013-01-25 2018-02-02 艾克斯赛尔生物科学公司 用于选择性富集靶细胞的方法、组合物、试剂盒及系统
DE102013010528B3 (de) * 2013-06-25 2014-02-20 FLACOD GmbH Verfahren zur Erstellung einer Datenbank für die Vorabschätzung der Wirksamkeit von Wirkstoffen in der Tumortherapie
EP3689467A1 (de) 2014-06-02 2020-08-05 Agilent Technologies, Inc. Einspaltiges mikroplattensystem und träger zur analyse biologischer proben
DK3198035T3 (da) 2014-09-26 2023-01-30 Allarity Therapeutics Europe ApS Fremgangsmåder til forudsigelse af medicinrespons
US9566012B2 (en) 2014-10-27 2017-02-14 Medtronic, Inc. Method and apparatus for selection and use of virtual sensing vectors
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423145A (en) * 1981-05-07 1983-12-27 Stampfer Martha R Enhanced growth medium and method for culturing human mammary epithelial cells
US4668618A (en) 1981-09-14 1987-05-26 Thornthwaite Jerry T Nuclear isolation medium and procedure for separating cell nuclei
US4937187A (en) * 1983-02-04 1990-06-26 Brown University Research Foundation Methods for separating malignant cells from clinical specimens
US4559299A (en) * 1983-02-04 1985-12-17 Brown University Research Foundation Inc. Cytotoxicity assays in cell culturing devices
US4816395A (en) * 1985-12-19 1989-03-28 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US4996145A (en) * 1987-10-27 1991-02-26 Oncotech Incorporated Method for detecting immune-mediated cytotoxicity
US5242806A (en) * 1990-05-07 1993-09-07 Baxter Diagnostics Inc. Method for conducting the cytotoxicity assays on tumor cells
US5874218A (en) 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5270172A (en) * 1991-04-26 1993-12-14 Dekk-Tek, Inc. Method to predict tumor response to therapy
US5407653A (en) * 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
EP0610441A4 (de) * 1991-10-29 1996-01-10 Clover Cons Ltd Vernetzbare polysacchariden, polykationen und lipiden verwendbar zum einkapseln und abgabe von arzneimitteln.
WO1994000470A1 (en) 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
GB9419716D0 (en) 1994-09-30 1994-11-16 Gearey David Electrochemical assessment of cell behaviour and metabolic activity
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5888765A (en) 1995-06-23 1999-03-30 President And Fellows Of Harvard College Endothelial-cell specific promoter
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US20040023375A1 (en) 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US20040072722A1 (en) * 2002-10-10 2004-04-15 Kornblith Paul L. Methods for assessing efficacy of chemotherapeutic agents
US6416967B2 (en) * 1996-07-12 2002-07-09 Precision Therapeutics, Inc. Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
US20020168679A1 (en) * 1998-06-11 2002-11-14 Gregory J. Naus Staining agents and protocols for characterizing malignant cells in culture
US5728541A (en) * 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US6008007A (en) * 1997-01-31 1999-12-28 Oncotech, Inc. Radiation resistance assay for predicting treatment response and clinical outcome
US5840507A (en) * 1997-03-19 1998-11-24 Oncotech, Inc. Methods for cancer prognosis and diagnosis
US5972639A (en) * 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
US6074874A (en) 1997-08-29 2000-06-13 University Of Pittsburgh Epithelial cell cultures for in vitro testing
US6111092A (en) * 1998-06-03 2000-08-29 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding DRT111 and uses thereof
US6664062B1 (en) * 1998-07-20 2003-12-16 Nuvelo, Inc. Thymidylate synthase gene sequence variances having utility in determining the treatment of disease
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
EP1059352A1 (de) 1999-06-08 2000-12-13 Oncodia AG Langzeitkultur humaner Karzinome
US6511806B1 (en) * 1999-11-03 2003-01-28 Oncotech, Inc. Methods for cancer prognosis and diagnosis
AU1760001A (en) * 1999-11-10 2001-06-06 Quest Diagnostics Investments Incorporated Use of computationally derived protein structures of genetic polymorphisms in pharmacogenomics and clinical applications
AU2001240998A1 (en) * 2000-03-06 2001-09-17 Technion Research And Development Foundation Ltd. Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy
US7206699B2 (en) * 2000-04-18 2007-04-17 Virco N.V. Methods for measuring therapy resistance
AU2002224435A1 (en) 2000-10-18 2002-04-29 Precision Therapeutics, Inc. Method for tandem genomic/proteomic analyses of proliferating cells
AU2002249946C1 (en) * 2001-01-12 2009-09-24 Washington State University mdr1 variants and methods for their use
US20040086888A1 (en) 2001-10-18 2004-05-06 Kornblith Paul L Method for tandem genomic/proteomic analysis of proliferating cells
JP3923366B2 (ja) * 2001-10-24 2007-05-30 財団法人癌研究会 細胞の抗癌剤感受性の判定法
US7767390B2 (en) * 2001-11-20 2010-08-03 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
JP2009506777A (ja) 2005-09-01 2009-02-19 プレシジョン セラピューティクス，インコーポレイテッド 抵抗性の表現型特徴を示す腫瘍細胞を用いた化学療法感受性アッセイ

Also Published As

Publication number Publication date
US8039213B2 (en) 2011-10-18
US20040072722A1 (en) 2004-04-15
WO2004035833A1 (en) 2004-04-29
US20090286255A1 (en) 2009-11-19
US20110020826A1 (en) 2011-01-27
US7829288B2 (en) 2010-11-09
AU2003285866A1 (en) 2004-05-04
US20080032298A1 (en) 2008-02-07
ATE449869T1 (de) 2009-12-15
EP1556515A4 (de) 2007-11-07
US7575868B2 (en) 2009-08-18
EP1556515A1 (de) 2005-07-27
EP1556515B1 (de) 2009-11-25

Similar Documents

Publication Publication Date Title
ATE449869T1 (de) Verfahren zur beurteilung der wirksamkeit von chemotherapeutika
DE602004027761D1 (de) Verfahren zum Auswählen und Aufnehmen von Tierzellenkolonien
ATE387194T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
DK1597391T3 (da) Anvendelse af intron-RNA til måling af genekspression
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
BRPI0415180A (pt) bateria
DE602005024113D1 (de) Batterie-elektrodenplatte und batterie-elektrodenplatten-herstellungsverfahren
IL179441A (en) Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme
EA200800951A1 (ru) Устройство и способ для оценивания ценностного показателя рабочего процесса и определения разрывов в текущем и желаемом состояниях
ATE488763T1 (de) Verfahren zur identifizierung von sich auf einen zellzustand auswirkenden bedingungen
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
ATE403151T1 (de) Trägerplatte zur durchführung funktioneller tests an biologischen zellen sowie verfahren zur beschichtung der trägerplatte
DE602004027070D1 (de) Verfahren und vorrichtung zum positionieren beim ersatz von anoden in einer elektrolysezelle
CY1110138T1 (el) Προσδιορισμος υψηλης διεκπεραιωτικοτητας της δραστικοτητας lp-pla2
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
WO2005006949A3 (en) Methods for predicting development of auto-immune diseases and treatment of same
DE60211958D1 (de) Schwefelhaltiger automatenstahl
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür
TW200501988A (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
ATE358673T1 (de) Nf-kb-inhibitoren
DE502004011753D1 (de) Verwendung von pit-emulsionen in enzymatischen reaktionen
DE60326773D1 (de) Peptid-deformylase-hemmer
ATE400814T1 (de) Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum
ATE408712T1 (de) Verfahren zur bestimmung des wiederauftretens von prostata krebs
DE602006018513D1 (de) Assoziation von pde4d-allelvarianten mit schlaganfall

Legal Events

Date Code Title Description
8364 No opposition during term of opposition